4SC pulls plug on do­mati­no­s­tat; Pharm­ing says le­niolis­ib meets both end­points

The man­age­ment board of 4SC has dis­con­tin­ued its do­mati­no­s­tat pro­gram af­ter the most re­cent clin­i­cal da­ta has been re­leased, the com­pa­ny an­nounced Tues­day.

The oral­ly ad­min­is­tered small mol­e­cule class I se­lec­tive in­hibitor was be­ing de­vel­oped for cas­es of ad­vanced cu­ta­neous melanoma. The com­pa­ny will shift its fo­cus to resmi­no­s­tat, an oral­ly bioavail­able in­hibitor that was grant­ed or­phan drug des­ig­na­tion to treat he­pa­to­cel­lu­lar car­ci­no­ma. The com­pa­ny says it has enough cash to be fund­ed through its RES­MAIN study of resmi­no­s­tat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER